(0.29%) 5 195.92 points
(0.17%) 38 917 points
(0.20%) 16 382 points
(0.46%) $78.84
(0.46%) $2.21
(-0.32%) $2 323.80
(-0.16%) $27.57
(2.61%) $990.05
(0.11%) $0.929
(0.69%) $10.90
(0.35%) $0.799
(-0.08%) $91.27
Quarter results today
(bmo 2024-05-07)
Expected move: +/- 10.17%
-6.27% $ 12.14
@ $0.740
Wydano: 13 vas. 2024 @ 19:37
Zwrot: 1 540.76%
Poprzedni sygnał: vas. 13 - 18:13
Poprzedni sygnał:
Zwrot: 0.58 %
Live Chart Being Loaded With Signals
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies...
Stats | |
---|---|
Dzisiejszy wolumen | 1.00M |
Średni wolumen | 800 355 |
Kapitalizacja rynkowa | 246.26M |
EPS | $0 ( 2024-03-14 ) |
Następna data zysków | ( $-3.10 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.880 |
ATR14 | $0.0500 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-03 | Armen Garo H | Buy | 1 248 | Common Stock |
2024-02-05 | Hirsch Susan B | Buy | 5 000 | Stock Option |
2024-02-05 | Wiinberg Ulf | Buy | 5 000 | Stock Option |
2024-02-05 | Corvese Brian | Buy | 15 000 | Stock Option |
2024-02-05 | Jeynes-ellis Allison M | Buy | 5 000 | Stock Option |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 11 180 436 | Sell: 367 647 |
Wolumen Korelacja
Agenus Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
BTTX | 0.967 |
OMCL | 0.963 |
CDMO | 0.962 |
SCPH | 0.961 |
SVRE | 0.957 |
SILK | 0.957 |
OMER | 0.956 |
LIFE | 0.951 |
CFRX | 0.951 |
CVAC | 0.951 |
10 Najbardziej negatywne korelacje | |
---|---|
FRSG | -0.974 |
IVCB | -0.973 |
TBSA | -0.97 |
LEGA | -0.968 |
CPAQ | -0.968 |
AHRN | -0.967 |
LGAC | -0.967 |
FTPA | -0.967 |
ACQR | -0.966 |
HORI | -0.966 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Agenus Inc Korelacja - Waluta/Towar
Agenus Inc Finanse
Annual | 2023 |
Przychody: | $156.31M |
Zysk brutto: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2023 |
Przychody: | $156.31M |
Zysk brutto: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2022 |
Przychody: | $98.02M |
Zysk brutto: | $-99.24M (-101.24 %) |
EPS: | $-0.960 |
FY | 2021 |
Przychody: | $295.67M |
Zysk brutto: | $113.59M (38.42 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej